140 related articles for article (PubMed ID: 16224162)
1. Immunoexpression of HBME-1, high molecular weight cytokeratin, cytokeratin 19, thyroid transcription factor-1, and E-cadherin in thyroid carcinomas.
Choi YL; Kim MK; Suh JW; Han J; Kim JH; Yang JH; Nam SJ
J Korean Med Sci; 2005 Oct; 20(5):853-9. PubMed ID: 16224162
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules.
Park YJ; Kwak SH; Kim DC; Kim H; Choe G; Park DJ; Jang HC; Park SH; Cho BY; Park SY
J Korean Med Sci; 2007 Aug; 22(4):621-8. PubMed ID: 17728499
[TBL] [Abstract][Full Text] [Related]
4. Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high-molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenoma.
Tan A; Etit D; Bayol U; Altinel D; Tan S
Ann Diagn Pathol; 2011 Apr; 15(2):108-16. PubMed ID: 21315633
[TBL] [Abstract][Full Text] [Related]
5. Reduced HBME-1 immunoreactivity of papillary thyroid carcinoma and papillary thyroid carcinoma-related neoplastic lesions with Hürthle cell and/or apocrine-like changes.
Mai KT; Bokhary R; Yazdi HM; Thomas J; Commons AS
Histopathology; 2002 Feb; 40(2):133-42. PubMed ID: 11952857
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
7. Expression of cytokeratin 19, HBME-1 and galectin-3 in neoplastic and nonneoplastic thyroid lesions.
Mataraci EA; Ozgüven BY; Kabukçuoglu F
Pol J Pathol; 2012 Mar; 63(1):58-64. PubMed ID: 22535608
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.
Abd-El Raouf SM; Ibrahim TR
Pathol Res Pract; 2014 Dec; 210(12):971-8. PubMed ID: 25041837
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical profile of common epithelial neoplasms arising in the kidney.
Kim MK; Kim S
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):332-8. PubMed ID: 12613443
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
[TBL] [Abstract][Full Text] [Related]
11. Paired box gene 8, HBME-1, and cytokeratin 19 expression in preoperative fine-needle aspiration of papillary thyroid carcinoma: diagnostic utility.
Schmitt AC; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Aug; 118(4):196-202. PubMed ID: 20731005
[TBL] [Abstract][Full Text] [Related]
12. Thyroid transcription factor-1, thyroglobulin, cytokeratin 7, and cytokeratin 20 in thyroid neoplasms.
Bejarano PA; Nikiforov YE; Swenson ES; Biddinger PW
Appl Immunohistochem Mol Morphol; 2000 Sep; 8(3):189-94. PubMed ID: 10981870
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin expression profiles in thyroid carcinomas.
Lam KY; Lui MC; Lo CY
Eur J Surg Oncol; 2001 Nov; 27(7):631-5. PubMed ID: 11669590
[TBL] [Abstract][Full Text] [Related]
14. Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.
Casey MB; Lohse CM; Lloyd RV
Endocr Pathol; 2003; 14(1):55-60. PubMed ID: 12746563
[TBL] [Abstract][Full Text] [Related]
15. Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma.
Miettinen M; Franssila KO
Hum Pathol; 2000 Sep; 31(9):1139-45. PubMed ID: 11014583
[TBL] [Abstract][Full Text] [Related]
16. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid.
Rossi ED; Raffaelli M; Mule' A; Miraglia A; Lombardi CP; Vecchio FM; Fadda G
Histopathology; 2006 Jun; 48(7):795-800. PubMed ID: 16722927
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of necrotic and degenerate thyroid lesions: value of immunohistochemistry.
Chai SM; Kumarasinghe MP
Histopathology; 2011 Sep; 59(3):496-503. PubMed ID: 22034889
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin and cytokeratin subtype profiling in effusion cytology.
Han J; Kim MK; Nam SJ; Yang JH
J Korean Med Sci; 2004 Dec; 19(6):826-33. PubMed ID: 15608393
[TBL] [Abstract][Full Text] [Related]
20. Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.
Barut F; Onak Kandemir N; Bektas S; Bahadir B; Keser S; Ozdamar SO
Endocr Pathol; 2010 Jun; 21(2):80-9. PubMed ID: 20198455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
